Citations

Showing 10 of 108094 citations.

Erfassung der Körperzusammensetzung
Schmidt, Steffen , Krell-Rösch, Janina

Mayo Clinic

B&G Bewegungstherapie und Gesundheitssport | May 15, 2018 | Volume: 34 | Issue: 02 | Pages: 82-87

10.1055/a-0569-6669 Get It

PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT)
He, Rong , Viswanatha, David S., Chen, Dong , Dyke, Daniel Van, Tian, Shulan , Dao, Linda N. , Call, Timothy G. , Ansell, Stephen M. , Leis, José F., Mai, Ming, Hanson, Curtis A. , Chen, Dong , Ding, Wei , Shi, Min , Dyke, Daniel L. Van , Parikh, Sameer A. , Shanafelt, Tait D. , Rech, Karen L.

Mayo Clinic

American Journal of Surgical Pathology | May 15, 2018 | Volume: 42 | Issue: 7 | Pages: 843-854

10.1097/pas.0000000000001077 | PMID 29762141 Get It

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a low-grade B-cell neoplasm and ∼2% to 9% patients develop an aggressive lymphoma, most commonly diffuse large B-cell lymphoma (Richter transformation, DLBCL-RT). Programmed death-1 (PD-1) pathway plays a crucial role in tumor host immunity evasion and its blockade has emerged as an effective anti-cancer immunotherapy. PD-L1 and PD-1 expression has shown predictive value in anti-PD cancer immunotherapy; however, it has not been well documented in CLL/SLL and DLBCL-RT. We evaluated PD-1 and PD-L1 expression by immunohistochemistry in 39 CLL/SLL, 15 DLBCL-RT, and 26 other DLBCL. In CLL/SLL, neoplastic B-cell PD-1 expression was weak and restricted to prolymphocytes/paraimmunoblasts within proliferation centers (PCs) and accentuated PCs of all sizes. Neoplastic B-cell PD-1 expression was highly prevalent and demonstrated increased intensity in DLBCL-RT, but in contrast was only rarely seen in other DLBCL (12/15 vs. 1/26; P<0.0001). An excellent correlation (90% concordance) was observed between neoplastic B-cell PD-1 immunohistochemistry positivity and molecularly defined CLL/SLL clonal relatedness in DLBCL-RT. PD-L1 expression was observed on the neoplastic B cells in rare DLBCL-RT and other DLBCL cases (1/15 vs. 1/26; P>0.05) as well as background histiocytes and dendritic cells. Overall survival of DLBCL-RT was significantly inferior to that of the other DLBCL (median, 16.9 vs. 106.1 mo; P=0.002). Our findings suggest a biological continuum from prolymphocytes/paraimmunoblasts in CLL/SLL PCs to the neoplastic B-cells in DLBCL-RT. The characteristic PD-1 expression in DLBCL-RT makes it a potential surrogate marker for determining clonal relatedness to CLL/SLL, which may have important prognostic and therapeutic implications.
On Reporting of the Outcomes from Clinical Trials; a Call to Order
Heilman, Raymond L. , Srinivas, Titte R. , Kaplan, Bruce

Mayo Clinic

Transplantation | May 15, 2018 | Volume: 102 | Issue: 12 | Pages: 1966-1967

10.1097/tp.0000000000002279 | PMID 29762457 Get It

Abstract B07: Role of lysyl hydroxylases in metastatic lung cancer
Guo, Lixia , Wang, Yuanyuan , Yang, Yanan, Liu, Wei , Zhang, Ting

Mayo Clinic

Cancer Research | May 15, 2018 | Volume: 78 | Issue: 10_Supplement | Pages: B07-B07

10.1158/1538-7445.mousemodels17-b07 Get It

Abstract Lung cancer remains the leading cause of cancer-related death, partly due to the fact that most patients are diagnosed with metastatic disease, which is the main cause of death, yet effective therapeutics are lacking. Utilizing mouse models of metastatic lung adenocarcinomas, we report that the transcription factor GATA3 and its cofactor FOG2 play critical roles in lung adenocarcinoma metastasis by promoting the expression of the lysyl hydroxylase (LH) family members, which in turn regulate the tumorigenicity and motility of lung tumor cells through both EMT and EMT-independent mechanisms. In vivo, LHs are elevated in human lung adenocarcinomas and are associated with worse patient survival. Collectively, our data suggest that targeting LHs may be useful for treating metastatic lung cancer. Citation Format: Wei Liu, Ting Zhang, Lixia Guo, Yuanyuan Wang, Yanan Yang. Role of lysyl hydroxylases in metastatic lung cancer [abstract]. In: Proceedings of the AACR Special Conference: Advances in Modeling Cancer in Mice: Technology, Biology, and Beyond; 2017 Sep 24-27; Orlando, Florida. Philadelphia (PA): AACR; Cancer Res 2018;78(10 Suppl):Abstract nr B07.
Preoperative Analysis of Venous Anatomy Before Deep Inferior Epigastric Perforator Free-Flap Breast Reconstruction Using Ferumoxytol-enhanced Magnetic Resonance Angiography
Dortch, John D. , Forte, Antonio J. , Bolan, Candice W. , Kandel, Pujan , Bolan, Candice, Forte, Antonio Jorge , Perdikis, Galen

Mayo Clinic

Annals of Plastic Surgery | May 15, 2018 | Volume: 90 | Issue: 4 | Pages: 343-348

10.1097/sap.0000000000001421 | PMID 29762436 Get It

Background Venous congestion after deep inferior epigastric artery perforator (DIEP) flap breast reconstruction is a complication that may be partially attributable to variations in venous abdominal wall anatomy. In previous work, we have shown that ferumoxytol may be used as a bloodpool contrast agent to perform high-resolution venous imaging. Our current aim was to use this technology to perform a detailed analysis of the venous anatomy among patients undergoing DIEP flap breast reconstruction. Methods All patients undergoing DIEP flap reconstruction with preoperative ferumoxytol-enhanced magnetic resonance angiography (FE-MRA) were retrospectively reviewed. A detailed anatomic analysis of each abdominal wall on FE-MRAwas performed before review of operative findings. Statistical analysis was used to determine venous characteristics associated with superficial inferior epigastric vein (SIEV) augmentation. Results From 2012 to 2016, 59 patients underwent preoperative FE-MRA. This resulted in imaging for 118 hemiabdomen and 99 flaps. Superficial-deep communication was identified in 117 of 118 hemiabdomen. Fifty (93%) of 59 patients had greater than 1-mm venous communication of the superficial system across midline. Reconstructed breasts were based on dominant medial row perforators in 82 (83%) of 99 flaps. The mean diameters of the SIEVand dominant venous perforator were 3.8 and 2.8mm, respectively. Anatomic characteristics associated with SIEVaugmentation included SIEVdiameter ( P = 0.01), dominant perforator diameter ( P = 0.04), and the ratio between these 2 variables ( P = 0.001). Conclusions Ferumoxytol-enhanced magnetic resonance angiography provides excellent imaging of the venous system. Anatomic characteristics such as the diameter of the SIEVand the diameter of the dominant perforator may be useful in determining which flaps require venous augmentation using the SIEV.
Novel engineered tendon-fibrocartilage-bone composite with cyclic tension for rotator cuff repair
Liu, Qian , Qi, Jun , Liu, Haoyu , Thoreson, Andrew R. , Amadio, Peter C. , Moran, Steven L. , Steinmann, Scott P. , Gingery, Anne , Zhao, Chunfeng , Hatta, Taku, Zhao, Chunfeng , Liu, Qian , Hatta, Taku , Gingery, Anne

Mayo Clinic

Journal of Tissue Engineering and Regenerative Medicine | May 15, 2018 | Volume: 12 | Issue: 7 | Pages: 1690-1701

10.1002/term.2696 | PMID 29763517 Get It

Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health
Larkin, Lisa , Stuenkel, Cynthia A. , Bachmann, Gloria , Chism, Lisa Astalos, Kagan, Risa , Kaunitz, Andrew M., Krychman, Michael , Parish, Sharon J. , Pinkerton, JoAnn V. , Rowen, Tami S., Shapiro, Marla , Simon, James A. , Goldfarb, Shari, Kingsberg, Sheryl A. , Faubion, Stephanie S. , Partridge, Ann H.

Mayo Clinic

Menopause | May 15, 2018 | Volume: 25 | Issue: 6 | Pages: 596-608

10.1097/gme.0000000000001121 | PMID 29762200 Get It

Abstract The objective of The North American Menopause Society (NAMS) and The International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel was to create a point of care algorithm for treating genitourinary syndrome of menopause (GSM) in women with or at high risk for breast cancer. The consensus recommendations will assist healthcare providers in managing GSM with a goal of improving the care and quality of life for these women. The Expert Consensus Panel is comprised of a diverse group of 16 multidisciplinary experts well respected in their fields. The panelists individually conducted an evidence-based review of the literature in their respective areas of expertise. They then met to discuss the latest treatment options for genitourinary syndrome of menopause (GSM) in survivors of breast cancer and review management strategies for GSM in women with or at high risk for breast cancer, using a modified Delphi method. This iterative process involved presentations summarizing the current literature, debate, and discussion of divergent opinions concerning GSM assessment and management, leading to the development of consensus recommendations for the clinician. Genitourinary syndrome of menopause is more prevalent in survivors of breast cancer, is commonly undiagnosed and untreated, and may have early onset because of cancer treatments or risk-reducing strategies. The paucity of evidence regarding the safety of vaginal hormone therapies in women with or at high risk for breast cancer has resulted in avoidance of treatment, potentially adversely affecting quality of life and intimate relationships. Factors influencing decision-making regarding treatment for GSM include breast cancer recurrence risk, severity of symptoms, response to prior therapies, and personal preference. We review current evidence for various pharmacologic and nonpharmacologic therapeutic modalities in women with a history of or at high risk for breast cancer and highlight the substantial gaps in the evidence for safe and effective therapies and the need for future research. Treatment of GSM is individualized, with nonhormone treatments generally being first line in this population. The use of local hormone therapies may be an option for some women who fail nonpharmacologic and nonhormone treatments after a discussion of risks and benefits and review with a woman's oncologist. We provide consensus recommendations for an approach to the management of GSM in specific patient populations, including women at high risk for breast cancer, women with estrogen-receptor positive breast cancers, women with triple-negative breast cancers, and women with metastatic disease.
RNAi screening identifies a mechanosensitive ROCK-JAK2-STAT3 network central to myofibroblast activation
Oh, Raymond , Haak, Andrew J. , Smith, Karry M. J. , Ligresti, Giovanni , Choi, Kyoung Moo , Xie, Tiao , Wang, Shaohua , Walters, P. , Freeman, Michelle, Manlove, L., Chu, Vivian, Roden, Anja C. , Schymeinsky, Jürgen , Prakash, Y. S. , Vassallo, Robert , Tschumperlin, Daniel J. , Oh, Raymond S , Walters, Paula R, Freeman, Michelle R, Manlove, Logan J, Chu, Vivian M, Tschumperlin, Daniel J , Prakash, Y S , Vassallo, Robert , Thompson, Michael A. , Feghali‐Bostwick, Carol A. , Pabelick, Christina M.

Mayo Clinic

Journal of Cell Science | May 15, 2018 | Volume: 131 | Issue: 10 | Pages: No page available

10.1242/jcs.209932 | PMID 29678906 Get It

ABSTRACT Myofibroblasts play key roles in wound healing and pathological fibrosis. Here, we used an RNAi screen to characterize myofibroblast regulatory genes, using a high-content imaging approach to quantify α-smooth muscle actin stress fibers in cultured human fibroblasts. Screen hits were validated on physiological compliance hydrogels, and selected hits tested in primary fibroblasts from patients with idiopathic pulmonary fibrosis. Our RNAi screen led to the identification of STAT3 as an essential mediator of myofibroblast activation and function. Strikingly, we found that STAT3 phosphorylation, while responsive to exogenous ligands on both soft and stiff matrices, is innately active on a stiff matrix in a ligand/receptor-independent, but ROCK- and JAK2-dependent fashion. These results demonstrate how a cytokine-inducible signal can become persistently activated by pathological matrix stiffening. Consistent with a pivotal role for this pathway in driving persistent fibrosis, a STAT3 inhibitor attenuated murine pulmonary fibrosis when administered in a therapeutic fashion after bleomycin injury. Our results identify novel genes essential for the myofibroblast phenotype, and point to STAT3 as an important target in pulmonary fibrosis and other fibrotic diseases.
Patient-Related Risk Factors for Infection Following Ulnar Nerve Release at the Cubital Tunnel: An Analysis of 15,188 Cases
Tebo, Collin C., Degen, Ryan M. , Altchek, David W. , Werner, Brian C. , Camp, Christopher L. , Dines, Joshua S.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | May 15, 2018 | Volume: 6 | Issue: 5 | Pages: No page available

10.1177/2325967118772799 | PMID 29796400 Get It

Background: Although cubital tunnel release is a commonly performed orthopaedic procedure, the overall incidence of and independent risk factors for infection largely remain undefined in the current literature. Purpose: To establish the rate of postoperative infection after isolated cubital tunnel release and define relevant patient-related risk factors. Study Design: Case-control study; Level 3. Methods: All Medicare-insured patients undergoing ulnar nerve decompression at the cubital tunnel from 2010 through 2012 were identified. A multivariate binomial logistic regression analysis was utilized to evaluate the impact of patient-related risk factors for postoperative infection. Results: A total of 330 (2.17%) postoperative infections were identified in 15,188 cases. The majority (87%) were managed nonoperatively, while 13% required surgical debridement. The most significant risk factors for infection included hemodialysis use (odds ratio [OR], 2.47), chronic anemia (OR, 2.24), age <65 years (OR, 2.08), tobacco use (OR, 1.65), morbid obesity (OR, 1.53), inflammatory arthritis (OR, 1.43), depression (OR, 1.36), hyperlipidemia (OR, 1.33), male sex (OR, 1.32), and chronic lung disease (OR, 1.29). Conclusion: The present study was adequately powered to determine numerous patient-related risk factors for infection following cubital tunnel release.
The Effect of OnabotulinumtoxinA on Aura Frequency and Severity in Patients With Hemiplegic Migraine: Case Series of 11 Patients
Chen, Tiffany , Garza, Ivan , Robertson, Carrie E. , Chen, Tiffany Y, Dodick, David W. , Robertson, Carrie E

Mayo Clinic

Headache: The Journal of Head and Face Pain | May 15, 2018 | Volume: 58 | Issue: 7 | Pages: 973-985

10.1111/head.13317 | PMID 29762872 Get It

Background OnabotulinumtoxinA has been demonstrated to be effective for the preventive treatment of headache in individuals with chronic migraine and has been approved and recommended for this patient population. While the therapeutic effect of onabotulinumtoxinA on migraine headache is well documented, there is limited information on the effect of onabotulinumtoxinA on migraine aura. Objective Given the prolonged and often debilitating nature of aura in patients with hemiplegic migraine, our group sought to examine the effect of onabotulinumtoxinA on aura frequency and severity in this specific subset of migraine patients. Methods All clinical notes from July 1, 1994 to December 1, 2017 at our institution were retrospectively reviewed to identify patients diagnosed with hemiplegic migraine who received at least one set of onabotulinumtoxinA injections. Thirty‐four patients were identified; and of those, 23 were excluded due to incomplete documentation regarding aura symptoms at follow‐up visits. The clinical notes of the remaining 11 patients (4 with familial hemiplegic migraine [FHM] and 7 with sporadic hemiplegic migraine [SHM]) were reviewed, and the frequency and description of their headaches and aura before and after receiving onabotulinumtoxinA were recorded. Results Nine of the 11 patients in our series noted a decrease in the frequency, severity, and/or duration of their aura after receiving onabotulinumtoxinA. Of the 2 non‐responders, one was FHM and one was SHM. Of the 9 that noticed improved aura symptoms, 6 described a “wearing off” effect of onabotulinumtoxinA around week 9 or 10 of the 12‐week cycle, with subsequent improvement after the next round. Conclusion For 9 of 11 patients with hemiplegic migraine, onabotulinumtoxinA was helpful not only in reducing the frequency and severity of headaches but also in reducing the frequency and severity of the aura. In this manuscript, we speculate on potential pathophysiologic mechanisms that could have contributed to this effect.